Cardiology

Nomexor^®/Nomexor^® plus HCT

Nomexor^® is approved for the treatment of essential hypertension and for the treatment of stable mild and moderate chronic heart failure in addition to standard therapy in elderly patients over 70 years of age.

Nomexor^® consists of the two clinically active enantiomers, D- and L-nebivolol. It combines two pharmacological effects:

1. It is a competitive and selective β1-receptor blocker: this effect is attributed to the D-enantiomer

2. Mild vasodilation by NO release at the endothelium

Single and repeated administration of nebivolol reduces heart rate and blood pressure at rest and during exercise. During acute and chronic treatment of hypertensives with nebivolol, systemic vascular resistance is decreased. Despite a reduction in heart rate, the decrease in cardiac output at rest and during exercise remains limited because stroke volume increases. The clinical relevance of these hemodynamic differences compared with other β1-receptor blockers has not been fully elucidated. In hypertensive patients, nebivolol increases nitric oxide-mediated vascular response to acetylcholine, which is decreased in patients with endothelial dysfunction.

Nomexor^® plus HCT is the fixed-dose combination of the active ingredient nebivolol with hydrochlorothiazide and is approved for the treatment of essential hypertension.

The fixed-dose combination is indicated in patients whose blood pressure is adequately controlled by the concomitant administration of nebivolol 5 mg and hydrochlorothiazide 12.5 mg or 25 mg.

AT-WEB-11-10-2021